2[19]Spengler M,Hobler H,Cagatay M.Long-term tolerability of acarbose.In:Lefèbvre PJ,Standl E,editors.New aspects in diabetes.Treatment strategies with alpha-glucosidase inhibitors[J].De Gruyter,Berlin,1992,286.
3[20]Hollander PA.Safety profile of acarbose,an alpha glucosidase inhibitor[J].Drugs,1993,44(Suppl 2):47.
4[21]Gentile S,Turco S,Guarino G,et al.Aminotransferase activity and acarbose treatment in patients with type-2 diabetes[J].Diabetes Care,1999,22(7):1217.
6[1]Cockram CS.The epidemiology of diabetes mellitus in the Asiapacific region[J].HKMJ,2000,6(1):43.
7[2]Lebowitz HE.α-Glucosidase inhibitors as agents in the treatment of diabetes[J].Diabetes Review,1998,6(2):132.
8[3]Hoffmann J,Spengler M.Efficacy of 24-week monotherapy with acarbose,metformin or placebo in dietary-treated NIDDM patients:The Essen-Ⅱ Study[J].Am J Med,1997,103:483.
9[4]Hoffmann J,Spengler M.The Essen I Study:efficacy of 24 week monotherapy with acarbose,glibenclamide or placebo in NIDDM patients[J].Diabetes Care,1994,17(6):561.
10[5]Chiasson JL,Josse RG,Hunt JA,et al.The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus:a multicenter controlled clinical trial[J].Ann Intern Med,1994,121 (12):928.
